Key result
Structure-based 3D-ASOs strongly inhibited SARS-CoV-2 replication in human cells, with PRF3p reducing viral RNA by 96% at 20 μM compared to mock transfection.
Why the study?
Current ASO designs rely strictly on Watson-Crick base pairing, but RNA folding into structures often interferes with ASO hybridization.
Does structure-based design of 3D-ASOs inhibit SARS-CoV-2 replication in human cells?
Does structure-based design of 3D-ASOs inhibit SARS-CoV-2 replication in human cells?
Structure-based design of 3D-ASOs targeting SARS-CoV-2 RNA structures significantly inhibits viral replication in vitro, offering a novel approach for antiviral drug development.
No immediate clinical role; leaves open whether 3D-ASOs advance as SARS-CoV-2 antivirals.
Antisense oligonucleotides (ASOs) are an emerging class of drugs that target RNAs. Current ASO designs strictly follow the rule of Watson-Crick base pairing along target sequences. However, RNAs often fold into structures that interfere with ASO hybridization. Here we developed a structure-based ASO design method and applied it to target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our method makes sure that ASO binding is compatible with target structures in three-dimensional (3D) space by employing structural design templates. These 3D-ASOs recognize the shapes and hydrogen bonding patterns of targets via tertiary interactions, achieving enhanced affinity and specificity. We designed 3D-ASOs that bind to the frameshift stimulation element and transcription regulatory sequence of SARS-CoV-2 and identified lead ASOs that strongly inhibit viral replication in human cells. We further optimized the lead sequences and characterized structure-activity relationship. The 3D-ASO technology helps fight coronavirus disease-2019 and is broadly applicable to ASO drug development.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) studied SARS-CoV-2 infection. 3D-ASOs (PRF3p and SBD1) vs. Mock transfection or conventional ASOs was evaluated on Reduction of viral RNA (p=0.00002). Structure-based 3D-ASOs strongly inhibited SARS-CoV-2 replication in human cells, with PRF3p reducing viral RNA by 96% at 20 μM compared to mock transfection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: